髓系白血病
串扰
索拉非尼
癌症研究
化学
白血病
髓样
巨噬细胞
髓系细胞
细胞培养
THP1细胞系
下调和上调
细胞毒性
细胞
医学
阿扎胞苷
细胞因子
封锁
肿瘤微环境
K562细胞
作者
Ruoyang Shao,Peiru Chi,Zhiping Fan,Yuxin Bai,Zhonghui Jiang,Fang Dai,Tian Zhang,Guo Qiu,Fen Huang,Na Xu,Xiaofeng Yang,Kejing Li,Yueyang Zhong,Hua Jin,Jing Sun,Xi Xu,Yu Wang,Qifa Liu,Li Xuan
出处
期刊:Cell Reports
[Cell Press]
日期:2026-09-22
卷期号:45 (10): 118083-118083
标识
DOI:10.1016/j.celrep.2026.118083
摘要
Sorafenib maintenance post-transplantation reduces relapse via inducing graft-versus-leukemia (GVL) effect in FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) + acute myeloid leukemia (AML) undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT), but the mechanism remains unclear. In this study, we investigated the effect of sorafenib in bone marrow immune microenvironment using single-cell RNA sequencing (scRNA-seq) and explored the mechanisms. We found that sorafenib promoted the macrophage-natural killer (NK) cell crosstalk through interleukin (IL)-18, elevating NK cell cytotoxicity and GVL effect. Mechanistically, sorafenib inhibited the mitochondrial electron transport complex I and V, resulting in metabolic reprogramming, thereby promoting IL-18 production via increasing PKM2-RelA binding and IL-18 release via triggering caspase-3/GSDME-dependent pyroptosis in macrophages. Our findings unveil the mechanism by which sorafenib enhances GVL in the FLT3-ITD+ AML patients undergoing allo-HSCT, providing theoretical and practical basis for constructing new strategies to prevent relapse post-transplantation.
科研通智能强力驱动
Strongly Powered by AbleSci AI